SCHEMBL4667598

SCHEMBL4667598

FC(F)(F)c1ccc(-c2ccccc2COCCOCc2ccccc2-c2ccc(C(F)(F)F)cc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 3/20 0.60
FFAR1 O14842 2/20 0.51
FFAR4 Q5NUL3 2/20 0.51
KIF11 P52732 2/20 0.46
BACE1 P56817 2/20 0.42
MCL1 Q07820 1/20 0.40
AGXT P21549 1/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.38
AR P10275 1/20 0.38
ALDH1A1 P00352 2/20 0.38
TSHR P16473 1/20 0.38
CYP19A1 P11511 1/20 0.37
CYP11B1 P15538 1/20 0.37
CYP11B2 P19099 1/20 0.37
KDM4E B2RXH2 1/20 0.37
CYP1A2 P05177 1/20 0.37
POLB P06746 1/20 0.37
CYP2C19 P33261 1/20 0.37
HSD17B10 Q99714 1/20 0.37
IDO1 P14902 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL792034 0.83 TACR1 (0.52) TACR1FFAR1FFAR4KIF11BACE1
SCHEMBL5198493 0.79 PDK2 (0.53) TACR1FFAR1FFAR4KIF11BACE1
SCHEMBL5511135 0.77 KIF11 (0.50) TACR1FFAR1FFAR4KIF11BACE1
SCHEMBL2096005 0.77 KIF11 (0.50) TACR1FFAR1FFAR4KIF11BACE1
SCHEMBL5199432 0.77 KIF11 (0.50) TACR1FFAR1FFAR4KIF11BACE1
SCHEMBL13675366 0.77 KIF11 (0.50) TACR1FFAR1FFAR4KIF11BACE1
SCHEMBL5190986 0.77 FFAR4 (0.48) TACR1FFAR1FFAR4PTGDR2CYP1A2
SCHEMBL9295043 0.77 DPP4 (0.62) TACR1FFAR1FFAR4KIF11BACE1
SCHEMBL5240718 0.76 HRH1 (0.49) TACR1ALDH1A1HTR7
SCHEMBL17840160 0.75 KIF11 (0.68) KIF11BACE1ALDH1A1TSHRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1930308-A1 Pharmaceutical agents for the treatment of cerebral amyloidosis NYMOX CORPORATION (CA) 2008-06-11 EP disclosed
EP-0983222-B1 PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS NYMOX CORP (CA) 2007-11-28 EP disclosed
US-6518314-B1 For treating cerebral amyloidosis; compounds that impede the transformation of dense microspheres (DMS) into amyloid NYMOX CORPORATION (CA) 2003-02-11 US disclosed
EP-0983222-A1 PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS NYMOX CORPORATION (CA) 2000-03-08 EP disclosed
WO-1998052898-A1 PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS NYMOX CORPORATION (CA) 1998-11-26 WO disclosed